Tag: Sweden

Orrön Energy AB (“Orrön Energy” or “the Company”) is pleased to announce that it has entered into an agreement with Cloudberry Clean Energy ASA (“Cloudberry”) to combine the Company’s Nordic renewable energy platform and organisation, excluding the Karskruv windfarm, with Cloudberry (the “Transaction”), creating a leading Nordic independent power producer (“IPP”). As consideration for the Transaction, Orrön Energy will receive 27.01 percent of the shares in the enlarged Cloudberry, becoming its largest shareholder. In addition, loan balances and accrued interest of approximately MEUR 93 as of year-end 2025 will be settled or assumed by Cloudberry, and Orrön Energy will receive MEUR 4.2 in cash. Orrön Energy will take an active role in Cloudberry’s future growth through Board representation, bringing Orrön Energy’s and the Lundin Group’s experience of value creation into the combined entity. Orrön Energy will continue to own the Karskruv windfarm and its large-scale European development business, consisting of data centres, solar and battery projects.

Orrön Energy AB (”Orrön Energy” eller ”Bolaget”) meddelar att Bolaget har ingått ett avtal med Cloudberry Clean Energy ASA (”Cloudberry”) om att kombinera Bolagets nordiska plattform och organisation inom förnybar energi, exklusive vindkraftsparken Karskruv, med Cloudberry (”Transaktionen”), och därigenom skapa en ledande nordisk oberoende elproducent (”IPP”). Som ersättning för Transaktionen kommer Orrön Energy att erhålla 27,01 procent av aktierna i ett större Cloudberry, och därmed bli dess största aktieägare. Dessutom kommer utestående lån inklusive upplupen ränta som per utgången av 2025 uppgick till cirka 93 MEUR sammanlagt att regleras eller övertas av Cloudberry, och Orrön Energy kommer att erhålla 4,2 MEUR i kontant köpeskilling. Orrön Energy kommer att ta en aktiv roll i Cloudberrys framtida tillväxt genom styrelserepresentation och bidra med erfarenhet av värdeskapande från Lundin-gruppen till den sammanslagna verksamheten. Orrön Energy kommer fortsatt att äga vindkraftsparken Karskruv och den storskaliga projektverksamheten i Europa inom datacenter, solenergi och batterier.

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).